GLP-1 Compounding Lawsuits in 2026: Every Major Case and What It Means for Patients

Case 1: Novo Nordisk vs. Everyone

The pharmaceutical giant behind Ozempic and Wegovy has waged the most aggressive legal campaign in the compounding industry’s history. By early 2026, Novo Nordisk had filed 132 federal complaints across 40 states, obtaining 44 permanent injunctions against compounding operations.

Their legal strategy attacks compounders on multiple fronts:

Lanham Act trademark infringement: Compounders that use the names “Ozempic” or “Wegovy” in their marketing — even in comparative statements like “same as Ozempic” — face trademark claims. The compounded product is semaglutide, not Ozempic, and using the brand name creates a false association.

False advertising: Claims that compounded products are “FDA-approved,” “equivalent,” or “generic versions” of branded products violate false advertising laws. There is no generic semaglutide approved in the United States.

“Sham personalization”: Novo Nordisk has argued that many compounders use the 503A personalization requirement as a fig leaf, prescribing identical formulations to every patient with no genuine clinical rationale. Their internal testing of confiscated products has strengthened these claims, finding products with 24%+ impurities and some that contained no semaglutide at all.

In November 2025 alone, Novo Nordisk filed 14 new lawsuits. The pace of litigation shows no sign of slowing.

Case 2: OFA vs. FDA

The Outsourcing Facilities Association (OFA), representing 503B compounding facilities, challenged the FDA’s determination that the semaglutide and tirzepatide shortages had been resolved. Their argument: the FDA failed to account for the approximately 2 million patients being served by compounders, and the branded manufacturers couldn’t immediately absorb that volume without triggering a new shortage.

The OFA also contended that the FDA’s shortage resolution process constituted a “legislative rule” under the Administrative Procedure Act (APA) that required a public notice-and-comment period, which the FDA did not provide.

The courts largely sided with the FDA:

March 5, 2025: Judge Mark Pittman denied the OFA’s preliminary injunction regarding tirzepatide, finding the FDA’s administrative record (including inventory data from Eli Lilly) sufficiently demonstrated the shortage was resolved.

April 24, 2025: The court similarly denied the preliminary injunction regarding semaglutide.

These rulings effectively closed the door on legal mass production of GLP-1 medications by 503B outsourcing facilities. The case may continue through appeals, but the practical outcome is that 503B compounding of semaglutide and tirzepatide is no longer permitted.

Case 3: Hims & Hers — DOJ Referral

The most high-profile casualty of the enforcement wave was Hims & Hers Health, one of the largest telehealth platforms marketing compounded semaglutide. On February 6, 2026, the same day the FDA announced its latest enforcement actions under Commissioner Makary, Hims received a Department of Justice referral related to its compounded semaglutide products.

By February 7, 2026, Hims had pulled its compounded semaglutide products from the market. The DOJ referral signaled a potential criminal investigation — a significant escalation beyond the civil enforcement actions and warning letters that had characterized earlier FDA responses.

For patients who were using Hims for their compounded semaglutide, the abrupt discontinuation created immediate access challenges. The situation illustrated the risk of relying on any single provider in a legally contested market.

Case 4: State Attorney General Actions

State-level enforcement has often moved faster than federal action, targeting the most egregious operators:

Connecticut: Attorney General William Tong issued cease-and-desist letters to multiple medical spas, including CT Weight Loss Shot and Radiance Medspa, for engaging in the unauthorized practice of pharmacy and falsely claiming their compounded products were “FDA-approved generics.”

Illinois: Attorney General Kwame Raoul led a bipartisan coalition of 38 state attorneys general urging the FDA to take stronger action against counterfeit GLP-1 imports and “research chemical” websites.

Kansas: Federal and state authorities pursued settlements with compounding pharmacies for false claims submitted to federal healthcare programs and improper dispensing practices. Midwest Compounders and PharmScript of KS paid over $3.2 million combined in settlements.

Ohio: The attorney general sent warnings to medical spas in the Mahoning Valley for misleading drug marketing practices related to GLP-1 medications.

What This Means for Patients

The legal landscape may seem alarming, but for patients using legitimate compounded GLP-1 providers, the enforcement wave is actually a net positive. Here’s why:

Bad actors are being removed. The providers facing lawsuits and enforcement actions are primarily those that were making false claims, using unapproved salt forms, selling without prescriptions, or operating without proper licensure. Their removal improves overall market safety.

Legitimate providers remain operational. 503A pharmacies that meet all legal requirements — patient-specific prescriptions, documented clinical differentiation, proper licensure, base-form API — continue to operate. The legal framework hasn’t changed; enforcement is targeting those who were already operating outside it.

New alternatives are emerging. The Wegovy pill (approved December 2025, launched January 2026, starting at $149/month), the upcoming orforglipron (PDUFA April 10, 2026), and Medicare coverage expansion (July 2026) are creating new access pathways that reduce dependence on compounded products.

The key takeaway: verify your provider meets all legal requirements. If they do, the lawsuits affecting other companies don’t directly impact your access. If they don’t, it’s time to find one that does.